Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,537JPY
17 Aug 2018
Change (% chg)

¥-76 (-1.65%)
Prev Close
¥4,613
Open
¥4,600
Day's High
¥4,607
Day's Low
¥4,537
Volume
4,005,800
Avg. Vol
5,213,066
52-wk High
¥6,693
52-wk Low
¥4,203

Select another date:

Tue, Jul 31 2018

Photo

Shire profit edges higher ahead of Takeda sale

LONDON Shire , the London-listed pharmaceutical group being bought by Japan's Takeda , reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to $3.92 billion, just ahead of market expectations.

Shire profit edges higher ahead of Takeda sale

LONDON Shire , the London-listed pharmaceutical group being bought by Japan's Takeda , reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to $3.92 billion, just ahead of market expectations.

Takeda operating profit halves, looks to asset sales to shore up finances

TOKYO Japan's Takeda Pharmaceutical Co Ltd on Tuesday reported that its operating profit halved from the year-ago quarter, when the drugmaker had booked gains from asset sales.

Takeda operating profit halves, looks to asset sales to shore up finances

TOKYO Japan's Takeda Pharmaceutical Co Ltd on Tuesday reported that its operating profit halved from the year-ago quarter, when the drugmaker had booked gains from asset sales.

UPDATE 2-Takeda operating profit halves, looks to asset sales to shore up finances

* Shire-related costs helped push debt ratio higher (Adds details from news conference)

Takeda Q1 profit tumbles 49 pct after asset sales, hit by generic drug competition

TOKYO, July 31 Japan's Takeda Pharmaceutical Co Ltd on Tuesday reported a 49 percent fall in first-quarter operating profit, affected by asset sales booked in the same quarter a year earlier and by generic drug competition for blood cancer treatment Velcade in the U.S.

Japan's Takeda gains U.S. approval for $62 billion Shire buy

TOKYO Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion (46.9 billion pounds) acquisition of London-listed Shire Plc , taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker.

Japan's Takeda gains U.S. approval for $62 billion Shire buy

TOKYO Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion acquisition of London-listed Shire Plc, taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker.

UPDATE 2-Japan's Takeda gains US approval for $62 bln Shire buy

* Also needs approval from Takeda, Shire shareholders (Adds share movement)

Takeda gets key U.S. regulatory approval to buy Shire

TOKYO, July 10 Japan's Takeda Pharmaceutical Co Ltd said on Tuesday it received a key U.S. regulatory approval for its $62 billion deal to buy London-listed Shire Plc .

Select another date: